Study Review – Secukinumab vs adalimumab for active psoriatic arthritis

This is a review of the EXCEED study, secukinumab vs adalimumab for treatment of active psoriatic arthritis.

The study was conducted across 26 countries including Australia with 853 participants. Commentary is provided by Associate Professor Paul Bird, a Rheumatologist in private practice and Conjoint A/Professor at the University of New South Wales.

Please login below to download this issue (PDF)

Subscribe